Oncology bispecific antibody trial starts vs Antibody-drug conjugate trial starts
In 2025, oncology bispecific antibody trial starts worldwide stood at 317, against 349 for antibody-drug conjugate trial starts.
Change the pair
Compare different indicators
The series
Over time
Global, spaced by time. Both series are in count, so they share one axis; the legend names each line.
Oncology bispecific antibody trial starts and Antibody-drug conjugate trial starts
Unit: count · 12 observations
View the underlying data
| Indicator | Period | Type | Value |
|---|---|---|---|
| Oncology bispecific antibody trial starts | 2025 | Actual | 317 |
| Oncology bispecific antibody trial starts | 2024 | Actual | 226 |
| Oncology bispecific antibody trial starts | 2023 | Actual | 189 |
| Oncology bispecific antibody trial starts | 2022 | Actual | 130 |
| Oncology bispecific antibody trial starts | 2021 | Actual | 104 |
| Oncology bispecific antibody trial starts | 2020 | Actual | 61 |
| Antibody-drug conjugate trial starts | 2025 | Actual | 349 |
| Antibody-drug conjugate trial starts | 2024 | Actual | 282 |
| Antibody-drug conjugate trial starts | 2023 | Actual | 233 |
| Antibody-drug conjugate trial starts | 2022 | Actual | 176 |
| Antibody-drug conjugate trial starts | 2021 | Actual | 145 |
| Antibody-drug conjugate trial starts | 2020 | Actual | 101 |
Shared periods
Side by side
6 periods are published for both series as annual figures on the same basis. Comparing anything else would mean comparing different periods.
| Period | Oncology bispecific antibody trial starts | Antibody-drug conjugate trial starts |
|---|---|---|
| 2020 | 61 ClinicalTrials.gov | 101 ClinicalTrials.gov |
| 2021 | 104 ClinicalTrials.gov | 145 ClinicalTrials.gov |
| 2022 | 130 ClinicalTrials.gov | 176 ClinicalTrials.gov |
| 2023 | 189 ClinicalTrials.gov | 233 ClinicalTrials.gov |
| 2024 | 226 ClinicalTrials.gov | 282 ClinicalTrials.gov |
| 2025 | 317 ClinicalTrials.gov | 349 ClinicalTrials.gov |
Provenance
Where these numbers come from
Oncology bispecific antibody trial starts
Count of interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count.
6 observations charted in Global · source organisations: ClinicalTrials.gov
Antibody-drug conjugate trial starts
Count of interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count.
6 observations charted in Global · source organisations: ClinicalTrials.gov
Data published under CC BY 4.0. Series A as JSON · Series B as JSON
Keep exploring